The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

The company benefits from surging demand for diabetes and obesity treatments, including Mounjaro and Zepbound. According to DeepSeek ... LLY YTD stock price chart. Source: Finbold Regarding portfolio ...

Zepbound (tirzepatide) is a prescription injection that comes as a single-dose pen or single-dose vial. If your doctor prescribes Zepbound to you and you need to travel, there are certain things ...

Some peptides help promote weight loss by helping to regulate blood sugar levels, metabolism, and appetite. These medications may cause side effects and people must have a prescription to take them.

The researchers found that 69,213,936 prescriptions for OMDs were dispensed in the United States during the study period, (HealthDay News) — Prescriptions of obesity management drugs (OMDs) have ...

Not every product needs massive scale and a prefilled syringe (PFS) dosage form. In fact, Lilly made the move to market Zepbound in a single-dose vial through its direct-to-consumer platform, which ...

Higher volumes of drugs like Mounjaro, Zepbound, Verzenio, Jardiance and Taltz were partially offset by lower sales of Trulicity. Lilly’s new products also contributed to sales growth.